ClinicalTrials.gg
Active, not recruitingNCT01436968PrTK03Updated Oct 2, 2026

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

A Phase 3 interventional study of Aglatimagene besadenovec + valacyclovir and Placebo + valacyclovir in Prostate Cancer, sponsored by Candel Therapeutics, Inc.. Active, not recruiting at 73 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Candel Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Oct 2, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
711
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
172nd of 3,023
711 · median 48
Started
2011
with 129 others
Phase 3
284 of 3,596
42 open now
Primary completion
2024-08
later than 70 of 971 live
Registered
1,255th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 172nd largest by planned enrollment of the 3,023 interventional ones that give a count, is one of 130 that started in 2011, is one of 284 in phase 3, reaches primary completion later than 70 of the 971 other live ones, and was the 1,255th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms receive standard external beam radiation therapy. Short-term androgen deprivation therapy may be given but is not required.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • immunotherapy, cytotoxicity, tumor vaccine, prostate cancer, radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients having only one NCCN high-risk feature

    • NCCN Intermediate Risk is defined as having at least one of the following: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c
    • High Risk with a single high risk feature is defined as having only one of the following: PSA>20 ng/ml, Gleason score 8-10, or T3a
    • Excluded are those in the following risk groups: Low risk; High risk with more than 1 high risk factor; Locally advanced/very high risk=T3b-T4; : N1 or M1
  • Planning to undergo standard prostate-only external beam radiation therapy
  • Performance Status 0-2

Exclusion criteria

Exclusion Criteria include:

  • Liver disease, including known cirrhosis or active hepatitis
  • Patients on systemic (>10mg prednisone per day) or other drugs
  • Known + patients
  • Regional lymph node involvement or distant
  • Patients planning to receive whole pelvic irradiation
  • Prior treatment for prostate cancer, except TURP or ADT. For ADT, it may only be given for a maximum of 6 months
  • Patients who had or plan to have orchiectomy as the form of hormonal ablation
  • Known sensitivity or allergic reactions to acyclovir or valacyclovir
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
711 participants (estimated)

Study arms

  • Experimental
    ProstAtak®

    Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT

    Biological: Aglatimagene besadenovec + valacyclovir

  • Placebo comparator
    Control

    Placebo + valacyclovir + radiation therapy +/- ADT

    Biological: Placebo + valacyclovir

Interventions

  • BiologicalAglatimagene besadenovec + valacyclovir

    Drug pages: Aglatimagene besadenovec · Valacyclovir

    Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows: 1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation. 2. The second injection will be 0-3 days before initiation of radiation therapy. 3. The third injection will be 15-22 days after the 2nd injection. The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.

    Also known as: AdV-tk, CAN-2409

  • BiologicalPlacebo + valacyclovir

    Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows: 1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation. 2. The second injection will be 0-3 days before initiation of radiation therapy. 3. The third injection will be 15-22 days after the 2nd injection. The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.

06

What researchers measure

Primary outcomes

  1. Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.

    Time frame: Assessed at each visit every 6 months through year 5 until event occurs.

Secondary outcomes

  1. Prostate cancer specific survival and overall survival will be compared for the ProstAtak® arm versus the placebo control arm.

    Time frame: Assessed at each visit every 6 months through year 5 after which long-term follow up of general health status will continue yearly.

  2. PSA nadir will be compared for the ProstAtak® arm versus the placebo control arm.

    Time frame: Assessed at each visit every 6 months through year 5.

  3. Patient reported Health Related Quality of Life outcomes will be collected using the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire. The change in QOL over time will be compared for the ProstAtak® arm versus the placebo control arm.

    Time frame: Assessed at baseline and at 3, 6, 12, 18 and 24 months after completion of radiation.

  4. The safety profile will be characterized by collection of adverse event information and laboratory values during the treatment phase (until the completion of radiation). Data on late effects will be collected after radiation completion.

    Time frame: Assessed at each visit and continuously throughout the study.

07

Study locations

73 sites
08

References and documents

Publications

  • DeWeese TL, Manzanera A, Sylvester J, Wheeler T, Schroeder T, Gejerman G, Chesnut G, Facelle TM, Garzotto MG, Pieczonka C, Gandhi NM, Sukin S, Liss MA, Tutrone R, Mehlhaff B, Savage SJ, Goody M, Vogt J, Rao S, Polanco MLS, Barone F, Nichols WG, Tak PP; PrTK03 study team. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2026 Jun;27(6):673-685. doi: 10.1016/S1470-2045(26)00071-9. PubMed 42225101 ↗
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Aug 2024 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2011
First posted
Sep 20, 2011
Start
Sep 2011
Primary completionActual
Aug 2024
CompletionEst.
Dec 2030
Results delay requested
Jul 28, 2025
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 United States, 1 Puerto Rico)
  • Arizona Oncology Services Foundation · Phoenix, Mesa, Scottsdale, Sedona, United States
  • VA Caribbean Healthcare System · San Juan, Puerto Rico
Show 2 removed
  • Arizona Oncology Services Foundation · Multiple Locations, United States
  • VA Caribbean Healthcare System · San Juan, Puerto Rico
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Puerto Rico)
    • Arizona Oncology Services Foundation · Phoenix, Mesa, Scottsdale, Sedona, United States
    • VA Caribbean Healthcare System · San Juan, Puerto Rico
    Show 2 removed
    • Arizona Oncology Services Foundation · Multiple Locations, United States
    • VA Caribbean Healthcare System · San Juan, Puerto Rico
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01436968
Lead sponsor
Candel Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 20, 2011
Start date
Sep 2011
Primary completion
Aug 2024
Completion
Dec 2030 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aglatimagene besadenovec · Valacyclovir

Start the discussion